Interleukin-2 in Metastatic Kidney Cancer

Inclusion Criteria

• •1. Patients must have a histologic diagnosis of metastatic kidney cancer. Patients may have received prior systemic therapy or may be previously untreated
• •2. Patients must have bi-dimensional measurable disease on physical exam or radiologic studies.
• •3. ECOG performance status of 0 or 1 and estimated survival of at least 3 months.
• •4. White blood count of \> 3500/mm3, platelet count \> 100,000/mm3, hemoglobin \> 9.0 gm/dl; bilirubin, ALT, AST \< 3 x upper limit of normal; serum creatinine \< 2.0 mg/dl.
• •5. Patients must undergo a low-level cardiac stress test as a screen for possible atherosclerotic heart disease. Patients with a positive stress test would be excluded from this trial.
• •6. Patients with elevated temperatures \> 100.5 F must have sources of occult infection excluded.
• •7. Patients must be felt to have recovered from effects of prior therapy, such as \> 2 weeks after prior chemotherapy.
• •8. Patient consent must be obtained prior to entrance onto study.
• •9. Women of childbearing potential must have a negative pregnancy test and must take adequate precautions to prevent pregnancy during treatment